Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)

Management's Discussion and Analysis of Financial Condition and Results of Operations.

FORWARD-LOOKING STATEMENTS

The following discussion may contain forward-looking statements regarding the Company, its business prospects and its results of operations that are subject to certain risks and uncertainties posed by many factors and events that could cause the Company's actual business, prospects and results of operations to differ materially from those that may be anticipated by such forward-looking statements. These forward-looking statements reflect our view only as of the date of this report. The Company cannot guarantee future results, levels of activity, performance, or achievement. The Company does not undertake any obligation to update or correct any forward-looking statements.

Business Update

During the quarter ended March 31, 2026, the Company undertook a strategic transition toward the development of artificial intelligence-enabled healthcare technology solutions and related healthcare services infrastructure focused on Latin America.

On February 17, 2026, the Company entered into an Asset Purchase Agreement pursuant to which it acquired certain proprietary healthcare technology assets and intellectual property relating to an artificial intelligence-enabled healthcare analytics platform and a technology-enabled healthcare services coordination platform. The acquired assets include technologies intended to support data-driven healthcare analytics, patient monitoring, telehealth infrastructure, and related healthcare applications.

In connection with the Company's strategic transition, the Company also established and organized operations through its wholly-owned Venezuelan subsidiary, Inversiones Long 33, C.A., which is intended to serve as the Company's operating entity in Venezuela and support its broader Latin American business strategy.

During April 2026, certain intellectual property assets acquired by the Company were assigned to the subsidiary as part of an internal operational reorganization. Prior to such assignment, the subsidiary had no material operations, assets, liabilities, or standalone financial history.

Current activities are focused on organizational development, operational structuring, technology evaluation, regulatory planning, and business development initiatives related to the Company's intended healthcare technology platform and services model.

Results of Operations for the Three Months Ended March 31, 2026 and 2025

Revenues

We had no revenue for three months ended March 31, 2026 and 2025.

Operating Expenses

Operating expenses increased to $43,384 for the three months ended March 31, 2026, from $15,967 for the same period ended March 31, 2025.

The increase in operating expenses is the result of additional professional fees incurred during the three months ended March 31, 2026.

Other Income (Expenses)

We had other expenses of $9,429 for the three months ended March 31, 2026, as compared with other expenses of $8,488 for the three months ended March 31, 2025. The increase in other expenses is the result of increased interest expense incurred during the three months ended March 31, 2026.

Net Loss

We recorded a net loss of $52,813 for the three months ended March 31, 2026, as compared with a net loss of $24,455 for the three months ended March 31, 2025.

Liquidity and Capital Resources

Going concern - The accompanying financial statements have been prepared in US dollars and in accordance with accounting principles generally accepted in the United States ("GAAP") on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. During three months ended March 31, 2026, the Company incurred net losses of $52,813 and accumulated deficits of $29,653,599. These conditions raise substantial doubt about the Company's ability to continue as a going concern.

As of March 31, 2026, we had total current assets of $0 and total assets in the amount of $7,824,000. Our total current liabilities as of March 31, 2026 were $683,673. We had a working capital deficit of $683,673 as of March 31, 2026, compared with a working capital deficit of $630,860 as of December 31, 2025.

Operating activities used $28,384 in cash for the three months ended March 31, 2026, as compared with $19,015 used for the three months ended March 31, 2025. Our negative operating cash flows for 2026 and 2025 was largely the result of our net loss for those quarters, mainly offset by changes in operating assets and liabilities.

We used no cash in investing activities for the three months ended March 31, 2026 and 2025.

Cash flow provided from financing activities was $28,384 for the three months ended March 31, 2026, as compared with $19,015 provided by cash flows for financing activities during the three months ended March 31, 2025.

Based upon our current financial condition, we do not have sufficient cash to operate our business at the current level for the next twelve months. We intend to fund operations through increased sales and debt and/or equity financing arrangements, which may be insufficient to fund expenditures or other cash requirements. We plan to seek additional financing in a private equity offering to secure funding for operations. There can be no assurance that we will be successful in raising additional capital.